摘要
多发性骨髓瘤是一种单克隆浆细胞恶性增殖性疾病,约占血液系统恶性肿瘤的10%.近年来,由于造血干细胞移植的开展,包含新药如沙利度胺、来那度胺和万珂等的联合化疗的应用,使得MM患者的平均生存期得到了明显的延长.应根据患者的临床症状、身体状况及预后,制定个体化的综合治疗策略.就多发性骨髓瘤患者的治疗策略进行综述.
Multiple myeloma is a monoclonal plasma cell malignant proliferative disease,accounting for about10%of malignant tumors of blood system.In recent years,due to the application of hematopoietic stem celltransplantation and the application of MDT by combining new drug such as thalidomide,lenalidomide and bortezomib,the average survival of MM patients was significantly longer than before.The treatment strategy should beindividualized before treatment according to the patient's age,physical condition and complications.In this paper,the treatment strategy of multiple myeloma patients were reviewed.
作者
张晓芸
曾云
ZHANG Xiao-yun;ZENG Yun(Dept. of The Blood Oncology,The 2nd People’s Hospital of Qujing,Qujing Yunnan 655000;Dept. of Hematology,The 1st Affiliated of Kunming Medical University/ Blood Disease Research Center of Yunnan Province,Kunming Yunnan 650000,China)
出处
《昆明医科大学学报》
CAS
2016年第10期1-4,共4页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(81060046)
关键词
多发性骨髓瘤
诱导治疗
干细胞移植
巩固治疗
维持治疗
Multiple myeloma
Induction therapy
Stemcell transplantation
Consolidation treatment
Maintenance treatment
